CA2116967C - Antidepressants - Google Patents

Antidepressants Download PDF

Info

Publication number
CA2116967C
CA2116967C CA002116967A CA2116967A CA2116967C CA 2116967 C CA2116967 C CA 2116967C CA 002116967 A CA002116967 A CA 002116967A CA 2116967 A CA2116967 A CA 2116967A CA 2116967 C CA2116967 C CA 2116967C
Authority
CA
Canada
Prior art keywords
compound
reference example
mmol
nmr
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002116967A
Other languages
English (en)
French (fr)
Other versions
CA2116967A1 (en
Inventor
Fumio Suzuki
Junichi Shimada
Akio Ishii
Joji Nakamura
Shunji Ichikawa
Shigeto Kitamura
Nobuaki Koike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of CA2116967A1 publication Critical patent/CA2116967A1/en
Application granted granted Critical
Publication of CA2116967C publication Critical patent/CA2116967C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16B—DEVICES FOR FASTENING OR SECURING CONSTRUCTIONAL ELEMENTS OR MACHINE PARTS TOGETHER, e.g. NAILS, BOLTS, CIRCLIPS, CLAMPS, CLIPS OR WEDGES; JOINTS OR JOINTING
    • F16B37/00—Nuts or like thread-engaging members
    • F16B37/04—Devices for fastening nuts to surfaces, e.g. sheets, plates
    • F16B37/048—Non-releasable devices

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mechanical Engineering (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002116967A 1992-07-08 1993-07-07 Antidepressants Expired - Fee Related CA2116967C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18102592 1992-07-08
JP181025/92 1992-07-08
PCT/JP1993/000931 WO1994001114A1 (en) 1992-07-08 1993-07-07 Antidepressant

Publications (2)

Publication Number Publication Date
CA2116967A1 CA2116967A1 (en) 1994-01-20
CA2116967C true CA2116967C (en) 2003-08-19

Family

ID=16093453

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002116967A Expired - Fee Related CA2116967C (en) 1992-07-08 1993-07-07 Antidepressants

Country Status (11)

Country Link
US (1) US5543415A (enEXAMPLES)
EP (1) EP0628311B1 (enEXAMPLES)
JP (1) JP2928386B2 (enEXAMPLES)
AT (1) ATE216584T1 (enEXAMPLES)
CA (1) CA2116967C (enEXAMPLES)
DE (1) DE69331843T2 (enEXAMPLES)
DK (1) DK0628311T3 (enEXAMPLES)
ES (1) ES2176204T3 (enEXAMPLES)
NO (1) NO306237B1 (enEXAMPLES)
PT (1) PT628311E (enEXAMPLES)
WO (1) WO1994001114A1 (enEXAMPLES)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
WO1995023148A1 (fr) * 1994-02-23 1995-08-31 Kyowa Hakko Kogyo Co., Ltd. Derive de la xanthine
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
US5786360A (en) * 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
ATE325610T1 (de) * 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
ES2260061T3 (es) * 1999-10-29 2006-11-01 Kyowa Hakko Kogyo Co., Ltd. Composiciones farmaceuticas para trastornos relacionados con la alimentacion.
KR100701455B1 (ko) * 2001-02-15 2007-03-29 그레이트 레이크스 케미칼 코포레이션 하이드록시아릴 포스핀 옥사이드의 혼합물 및 이의 제조방법, 및 이로부터 유도된 에폭시 올리고머 생성물, 난연성 에폭시 조성물, 수지-함침된 복합물 및 적층물
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa
TR201903603T4 (tr) 2002-01-28 2019-04-22 Kyowa Hakko Kogyo Kk Hareket bozukluklarının tedavisinde kullanım için A2A reseptörü antagonistleri.
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
CA2516250A1 (en) 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
KR101229594B1 (ko) * 2003-05-09 2013-02-05 교와 핫꼬 기린 가부시키가이샤 미세 결정
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
JP2007506804A (ja) * 2003-06-09 2007-03-22 エンダセア， インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
BRPI0411120A (pt) * 2003-06-10 2006-07-18 Kyowa Hakko Kogyo Kk método para tratar de um distúrbio de ansiedade, composição, agente para tratar de um distúrbio de ansiedade, e, usos de um composto e de um derivado de xantina
TW200507850A (en) 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
CA2554426C (en) 2004-01-28 2012-10-16 Kyowa Hakko Kogyo Co., Ltd. Agents for treating migraine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
GB0719545D0 (en) * 2007-10-08 2007-11-14 Barry Callebaut Ag Novel use of cocoa extract
GB0719542D0 (en) * 2007-10-08 2007-11-14 Barry Callebaut Ag Use of cocoa extract
GB0719544D0 (en) * 2007-10-08 2007-11-14 Barry Callebaut Ag Cocoa extract and use thereof
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
RU2477726C1 (ru) * 2011-10-18 2013-03-20 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Замещенные феноксиуксусные кислоты, их эфиры и амиды, включающие 2,6-диоксо-2,3,6,7-тетрагидро-1н-пурин-8-иловый фрагмент, - антагонисты аденозинового a2a рецептора и их применение
CN104744464B (zh) * 2013-11-15 2016-09-21 南京华威医药科技开发有限公司 伊曲茶碱晶型
CN104262342B (zh) * 2014-08-26 2019-01-29 南京恒道医药科技有限公司 一种伊曲茶碱中间体的制备方法
CN105884776A (zh) * 2014-11-05 2016-08-24 南京瑞天医药科技有限公司 一种伊曲茶碱的新晶型及其制备方法
WO2020125779A1 (en) * 2018-12-21 2020-06-25 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
WO2020216152A1 (en) * 2019-04-24 2020-10-29 Dongguan Hec New Drug R&D Co., Ltd. 8-substituted aryl vinyl xanthine derivatives and uses thereof
CN110041331B (zh) * 2019-05-17 2020-08-07 广东东阳光药业有限公司 苯乙烯基黄嘌呤衍生物及其用途
CN111072663B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111018856B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
AU2021235803A1 (en) * 2020-03-10 2022-09-29 Marvel Biotechnology Purine compounds for treating disorders
CN113248505B (zh) * 2021-06-09 2021-09-21 南京安杰新生物医药有限公司 伊曲茶碱去甲基杂质的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641010A (en) * 1970-06-11 1972-02-08 Parke Davis & Co Novel xanthine compounds and means for obtaining the same
FR2531713A2 (fr) * 1981-09-16 1984-02-17 Panmedica Sa Nouvelles compositions a base de 5-hydroxytryptophane, leur procede de preparation et medicaments les contenant
FR2512672A1 (fr) * 1981-09-16 1983-03-18 Panmedica Nouvelles compositions a base de 5-hydroxytryptophane, leur procede de preparation et medicaments les contenant
DE3224100A1 (de) * 1982-06-29 1983-12-29 Michael 6950 Schriesheim Long Depotmedikament zur behandlung von psychologischen aberrationen, erkrankungen und dergleichen
US4769377A (en) * 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
JPH0256428A (ja) * 1988-08-19 1990-02-26 Rohto Pharmaceut Co Ltd 肥満症治療剤
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
WO1992006976A1 (fr) * 1990-10-18 1992-04-30 Kyowa Hakko Kogyo Co., Ltd. Derive de xanthine
IT1260444B (it) * 1992-01-24 1996-04-09 Mario Brufani Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease

Also Published As

Publication number Publication date
DE69331843D1 (de) 2002-05-29
JP2928386B2 (ja) 1999-08-03
CA2116967A1 (en) 1994-01-20
NO306237B1 (no) 1999-10-11
ES2176204T3 (es) 2002-12-01
US5543415A (en) 1996-08-06
DE69331843T2 (de) 2002-09-26
NO940737L (enEXAMPLES) 1994-05-03
EP0628311A1 (en) 1994-12-14
NO940737D0 (no) 1994-03-03
PT628311E (pt) 2002-09-30
WO1994001114A1 (en) 1994-01-20
EP0628311B1 (en) 2002-04-24
DK0628311T3 (da) 2002-07-22
JPH09502006A (ja) 1997-02-25
ATE216584T1 (de) 2002-05-15
EP0628311A4 (en) 1999-03-10

Similar Documents

Publication Publication Date Title
CA2116967C (en) Antidepressants
CA2107014C (en) Therapeutic agent for parkinson's disease
US5484920A (en) Therapeutic agent for Parkinson's disease
CA2093403C (en) Therapeutic agent for parkinson's disease
EP0698607B1 (en) Xanthine derivative
EP0607607B1 (en) Xanthine derivatives
HK1001835B (en) Therapeutic agents for use in the treatment of parkinson's disease
US6825349B2 (en) A2B adenosine receptor antagonists
ES2401128T3 (es) Derivados de xantina como agonistas selectivos de HM74A
AU2010289465B2 (en) Substituted xanthine derivatives
AU2009217680A1 (en) Substituted xanthine derivatives
EP1116722A1 (en) [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
CA2002834C (en) Cycloalkyl xanthines
HUP0200938A2 (en) Purine derivatives having phosphodiesterase iv inhibition activity and medicaments containing them
IL97656A (en) 1,3-dipropyl-8-aralkyl-xanthine derivatives process for their preparation and pharmaceutical compositions comprising them
IE44708B1 (en) Esters of hydroxyalkoxylkyl purines, their preparation, and pharmaceutical compositions containing them
GB1561380A (en) Esters of hydroxyalkoxyalkyl purines their preparation and pharmaceutical compositions containing them
HK1004551B (en) Xanthine derivatives, process for their preparation and pharmaceutical compositions.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed